BRPI0510043A - método de tratamento de dor neuropática usando antagonista de receptor crth2 - Google Patents

método de tratamento de dor neuropática usando antagonista de receptor crth2

Info

Publication number
BRPI0510043A
BRPI0510043A BRPI0510043-7A BRPI0510043A BRPI0510043A BR PI0510043 A BRPI0510043 A BR PI0510043A BR PI0510043 A BRPI0510043 A BR PI0510043A BR PI0510043 A BRPI0510043 A BR PI0510043A
Authority
BR
Brazil
Prior art keywords
receptor antagonist
neuropathic pain
crth2 receptor
treating neuropathic
treating
Prior art date
Application number
BRPI0510043-7A
Other languages
English (en)
Inventor
Laura Corradini
Mark John Field
Ross Anderson Kinloch
Bryn Ivor Williams-Jones
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0408799A external-priority patent/GB0408799D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0510043A publication Critical patent/BRPI0510043A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MéTODO DE TRATAMENTO DE DOR NEUROPáTICA USANDO ANTAGONISTA DE RECEPTOR CRTH2. A presente invenção refere-se ao uso de um antagonista de receptor de CRTH2 na fabricação de um medicamento para o tratamento de dor neuropática e a um método para tratar dor neuropática utilizando um antagonista de receptor de CRTH2.
BRPI0510043-7A 2004-04-20 2005-04-08 método de tratamento de dor neuropática usando antagonista de receptor crth2 BRPI0510043A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0408799A GB0408799D0 (en) 2004-04-20 2004-04-20 Method of treating pain
US59087104P 2004-07-22 2004-07-22
PCT/IB2005/000992 WO2005102338A1 (en) 2004-04-20 2005-04-08 Method of treating neuropathic pain using a crth2 receptor antagonist

Publications (1)

Publication Number Publication Date
BRPI0510043A true BRPI0510043A (pt) 2007-10-16

Family

ID=34964546

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510043-7A BRPI0510043A (pt) 2004-04-20 2005-04-08 método de tratamento de dor neuropática usando antagonista de receptor crth2

Country Status (7)

Country Link
US (1) US20090170897A1 (pt)
EP (1) EP1740179A1 (pt)
JP (1) JP2007533725A (pt)
BR (1) BRPI0510043A (pt)
CA (1) CA2563707A1 (pt)
MX (1) MXPA06011891A (pt)
WO (1) WO2005102338A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
EP1853234A2 (en) * 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
AU2006237365B2 (en) 2005-04-21 2012-09-20 Merck Serono Sa 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2
KR101333861B1 (ko) 2005-05-24 2013-11-28 메르크 세로노 에스. 에이. Ｃｒｔｈ２ 조정자로서 삼환계 스피로 유도체
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
JP5528705B2 (ja) 2005-12-13 2014-06-25 トリニティ ラボラトリーズ インコーポレイテッド ヒトにおける早漏を治療するための方法
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds
HUE030850T2 (en) 2006-06-16 2017-06-28 Univ Pennsylvania Prostaglandin D2 receptor antagonists for the treatment of hair loss
TR200703092A1 (tr) 2007-05-08 2008-12-22 SANOVEL �LA� SAN. VE TiC. A.�. Flurbiprofen ve kas gevşetici kombinasyonları
CA2710318A1 (en) * 2007-12-21 2009-07-09 Paz Arzneimittel-Entwicklungsgesellscaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
RS53142B (sr) * 2008-01-18 2014-06-30 Atopix Therapeutics Limited Jedinjenja koja imaju antagonističku aktivnost na crth2
US8168673B2 (en) 2008-01-22 2012-05-01 Oxagen Limited Compounds having CRTH2 antagonist activity
US8101645B2 (en) 2008-02-15 2012-01-24 Abbott Laboratories Thienopyrroles and pyrrolothiazoles as new therapeutic agents
WO2010092043A1 (en) 2009-02-12 2010-08-19 Merck Serono S.A. Phenoxy acetic acid derivatives
WO2010102154A2 (en) 2009-03-05 2010-09-10 Ligand Pharmaceuticals Incorporated Biaryl oxyacetic acid compounds
WO2011002814A2 (en) 2009-06-30 2011-01-06 Ligand Pharmaceuticals Inc. Biaryl oxyacetic acid compounds
TW201201805A (en) 2010-07-05 2012-01-16 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
CN104011021B (zh) 2011-12-21 2016-08-24 埃科特莱茵药品有限公司 杂环衍生物及其作为前列腺素d2受体调节剂的用途
US9169270B2 (en) 2012-07-05 2015-10-27 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN104634883B (zh) * 2013-11-07 2018-04-27 苏州普源精电科技有限公司 一种具有融合峰基线调整功能的色谱工作站
CN104634906B (zh) * 2013-11-07 2018-07-13 苏州普源精电科技有限公司 分离峰的基线调整方法和具有基线调整功能的色谱工作站
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201407820D0 (en) * 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
WO2016128565A1 (en) 2015-02-13 2016-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
WO2017019858A1 (en) 2015-07-30 2017-02-02 The Trustees Of The University Of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3486408B2 (ja) * 1999-08-23 2004-01-13 株式会社ビー・エム・エル 物質のヒトプロスタグランジンｄ２受容体に対する性質の同定方法
KR20040044856A (ko) * 2001-09-07 2004-05-31 오노 야꾸힝 고교 가부시키가이샤 인돌 유도체 화합물
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
CA2500083A1 (en) * 2002-10-21 2004-04-29 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
WO2004052863A1 (ja) * 2002-12-06 2004-06-24 Kyowa Hakko Kogyo Co., Ltd. 抗炎症剤
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
WO2005007094A2 (en) * 2003-07-09 2005-01-27 Tularik Inc. Asthma and allergic inflammation modulators

Also Published As

Publication number Publication date
WO2005102338A1 (en) 2005-11-03
JP2007533725A (ja) 2007-11-22
WO2005102338A8 (en) 2006-12-14
MXPA06011891A (es) 2007-04-24
EP1740179A1 (en) 2007-01-10
CA2563707A1 (en) 2005-11-03
US20090170897A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
BRPI0810354A2 (pt) Composto, uso de um composto, composição farmacêutica, e, método de tratamento de um dispositivo de dor
BRPI0607402A2 (pt) uso de inibidores de pde7 para o tratamento de dor neuropática
WO2005102338A8 (en) Method of treating neuropathic pain using a crth2 receptor antagonist
BRPI0919876A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
DE602007011908D1 (de) Verwendung von gpr119-rezeptoragonisten zur vermehrung der knochenmasse und zur behandlung von osteoporose sowie kombinationstherapie dafür
PT1765314T (pt) Composições farmacêuticas para o tratamento de doenças e sintomas em artrite reumatoide
BRPI0717769A2 (pt) Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio
BRPI0914902A2 (pt) composição farmacêutica e método para tratamento de mal de parkinson
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EP1851237A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING BONE DISORDERS
BRPI0615157A2 (pt) composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
ZA200808865B (en) Antibody composition and methods for treatment of neoplastic disease
BRPI0511995A (pt) uso de compostos peptìdicos para tratamento de dor em neuralgia trigeminal
ATE512948T1 (de) Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen
BRPI0509211A (pt) uso de compostos de peptìdeo para o tratamento de dor em neuropatia diabética
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
BRPI0909651A2 (pt) cristal, agente farmacêutico, método para tratar ou evitar doença, uso do cristal, e, método para a produção de um cristal
PT2054045E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor
EP1715820A4 (en) SPINE-facet joint IMPLANT
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
BRPI0514721A (pt) uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BRPI0921557A2 (pt) bacteriófago filamentoso, primeiro e segundo bacteriófago filamentoso para o uso no tratamento do mal de parkinson, composição farmacêutica, e , método para tratar um paciente
EA200970376A1 (ru) Peg-илированный паратиреоидный гормон в качестве модулятора рецептора паратиреоидного гормона и его применение

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.